✦ LIBER ✦

Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis

✍ Scribed by Stathis, P.; Smpiliris, M.; Konitsiotis, S.; Mitsikostas, D. D.

Book ID: 120211931
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 659 KB
Volume: 20
Category: Article
ISSN: 1351-5101
DOI: 10.1111/ene.12014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nocebo in clinical trials for depression

Nocebo in clinical trials for depression: A meta-analysis

✍ Mitsikostas, Dimos D.; Mantonakis, Leonidas; Chalarakis, Nikolaos 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 796 KB

Dopamine agonist monotherapy in Parkinso

Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials

✍ Chondrogiorgi, M.; Tatsioni, A.; Reichmann, H.; Konitsiotis, S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 633 KB

Pramipexole v. Levodopa as Initial Treat

Pramipexole v. Levodopa as Initial Treatment for Parkinson's Disease: A Randomized Clinical-Economic Trial

✍ Noyes, K. 📂 Article 📅 2004 🏛 SAGE Publications 🌐 English ⚖ 325 KB

Mesalamine in the maintenance treatment

Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables

✍ C Camma; M Giunta; M Rosselli; M Cottone 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Exenatide as a potential treatment for p

Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

✍ Foltynie, Thomas; Aviles-Olmos, Iciar 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 224 KB

Sarizotan as a treatment for dyskinesias

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio